Mostrar el registro sencillo del ítem

dc.contributor.authorVera Ramírez, Laura 
dc.contributor.authorSánchez Rovira, Pedro
dc.contributor.authorRamírez Tortosa, César Luis 
dc.contributor.authorQuiles Morales, José Luis 
dc.contributor.authorRamírez Tortosa, María Carmen 
dc.contributor.authorLorente Acosta, José Antonio 
dc.date.accessioned2014-03-12T09:03:49Z
dc.date.available2014-03-12T09:03:49Z
dc.date.issued2013
dc.identifier.citationVera-Ramírez, L.; et al. Transcriptional Shift Identifies a Set of Genes Driving Breast Cancer Chemoresistance. Plos One, 8(1): e53983 (2013). [http://hdl.handle.net/10481/30790]es_ES
dc.identifier.issn1932-6203
dc.identifier.otherdoi: 10.1371/journal.pone.0053983
dc.identifier.urihttp://hdl.handle.net/10481/30790
dc.description.abstractBackground Distant recurrences after antineoplastic treatment remain a serious problem for breast cancer clinical management, which threats patients’ life. Systemic therapy is administered to eradicate cancer cells from the organism, both at the site of the primary tumor and at any other potential location. Despite this intervention, a significant proportion of breast cancer patients relapse even many years after their primary tumor has been successfully treated according to current clinical standards, evidencing the existence of a chemoresistant cell subpopulation originating from the primary tumor.es_ES
dc.description.abstractMethods/Findings To identify key molecules and signaling pathways which drive breast cancer chemoresistance we performed gene expression analysis before and after anthracycline and taxane-based chemotherapy and compared the results between different histopathological response groups (good-, mid- and bad-response), established according to the Miller & Payne grading system. Two cohorts of 33 and 73 breast cancer patients receiving neoadjuvant chemotherapy were recruited for whole-genome expression analysis and validation assay, respectively. Identified genes were subjected to a bioinformatic analysis in order to ascertain the molecular function of the proteins they encode and the signaling in which they participate. High throughput technologies identified 65 gene sequences which were over-expressed in all groups (P ≤ 0·05 Bonferroni test). Notably we found that, after chemotherapy, a significant proportion of these genes were over-expressed in the good responders group, making their tumors indistinguishable from those of the bad responders in their expression profile (P ≤ 0.05 Benjamini-Hochgerg`s method).es_ES
dc.description.abstractConclusions These data identify a set of key molecular pathways selectively up-regulated in post-chemotherapy cancer cells, which may become appropriate targets for the development of future directed therapies against breast cancer.es_ES
dc.description.sponsorshipThanks are due to the Consejería de Economia, Innovación y Ciencia (CEIC) from the Junta de Andalucía and Fondo Europeo de Desarrollo Regional (FEDER)/Fondo de Cohesión Europeo (FSE) to financial support through the Programa Operativo FEDER/FSE de Andalucía 2007-2013 and the research project CTS-5350. The authors also acknowledge financial support by the PN de I+D+i 2006-2009/ISCIII/Ministerio de Sanidad, Servicios Sociales e Igualdad (Spain) and Fondo Europeo de Desarrollo Regional (FEDER) from the European Union, through the research project PI06/90388.es_ES
dc.language.isoenges_ES
dc.publisherPublic Library of Science (PLOS)es_ES
dc.subjectBreast canceres_ES
dc.subjectCancer stem cellses_ES
dc.subjectCancer treatmentes_ES
dc.subjectChemotherapyes_ES
dc.subjectGene expressiones_ES
dc.subjectGene targetinges_ES
dc.subjectGenetic networkses_ES
dc.subjectMicroarrayses_ES
dc.titleTranscriptional Shift Identifies a Set of Genes Driving Breast Cancer Chemoresistancees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem